ARVN (Arvinas) Inventories, Raw Materials & Components : $0.0 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Arvinas Inventories, Raw Materials & Components?

Arvinas's inventories, raw materials & components for the quarter that ended in Sep. 2024 was $0.0 Mil.

Arvinas Inventories, Raw Materials & Components Historical Data

The historical data trend for Arvinas's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arvinas Inventories, Raw Materials & Components Chart

Arvinas Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

Arvinas Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Raw Materials & Components	Get a 7-Day Free Trial															-	-	-	-	-

Arvinas Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

Arvinas Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arvinas Inc (NAS:ARVN) » Definitions » Inventories, Raw Materials & Components

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511

Website

https://www.arvinas.com

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Executives

David K Loomis	officer: Chief Accounting Officer	C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511
Ian Taylor	officer: Senior Vice President, Biology	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651
John G Houston	director, officer: President and CEO	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sean A Cassidy	officer: Chief Financial Officer	322 EAST MAIN STREET, BRANFORD CT 06405
Ronald Peck	officer: Chief Medical Officer	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sunil Agarwal	director	60 LEVERONI COURT, NOVATO CA 94949
Everett Cunningham	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
John D Young	director	C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Liam Ratcliffe	director, 10 percent owner	C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Timothy M Shannon	director	C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Bradley Albert Margus	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Kennedy Edward Moore Jr.	director	C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Wendy L Dixon	director
Linda Bain	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139